Erratum: P53 immunoexpression as a prognostic marker for human astrocytomas: A meta-analysis and review of the literature (Journal of Neuro-Oncology DOI: 10.1007/s11060-010-0204-y);P53 immunoexpression as a prognostic marker for human astrocytomas: A meta-analysis and review of the literature

Journal of Neuro-Oncology

Volumn 100, Issue 3, 2010, Pages 363-371

  Levidou, Georgia ^a   El Habr, Elias ^a   Saetta, Angelica A ^a   Bamias, Christine ^a   Katsougiannis, Klea ^a   Patsouris, Efstratios ^a   Korkolopoulou, Penelope ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Human astrocytomas; Immunoexpression; Meta analysis; P53

Indexed keywords

PROTEIN P53;

AGE; ARTICLE; ASTROCYTOMA; CANCER GRADING; CANCER MORTALITY; CANCER SURVIVAL; GLIOBLASTOMA; HUMAN; IMMUNOHISTOCHEMISTRY; PROGNOSIS; PROTEIN EXPRESSION; SYSTEMATIC REVIEW;

EID: 78449281662     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-010-0270-1     Document Type: Erratum

References (65)

1. DN Louis H Ohgaki OD Wiestler WK Cavenee PC Burger A Jouvet BW Scheithauer P Kleihues 2007 The 2007 WHO classification of tumors of the central nervous system Acta Neuropathol (Berl) 114 2 97 109 10.1007/s00401-007-0243-4
2. FB Furnari T Fenton RM Bachoo A Mukasa JM Stommel A Stegh WC Hahn KL Ligon DN Louis C Brennan L Chin RA DePinho WK Cavenee 2007 Malignant astrocytic glioma: genetics, biology, and paths to treatment Genes Dev 21 21 2683 2710 1:CAS:528:DC%2BD2sXhtlSitLrO 10.1101/gad.1596707 17974913
3. B Vogelstein D Lane A Levine 2000 Surfing the p53 network Nature 408 107 110 10.1038/35042675
4. N Ishii N deTribolet 1998 Are p53 mutations and p53 overexpression prognostic factors for astrocytic tumors? Crit Rev Neurosurg 8 269 274 10.1007/s003290050087 9732540
5. C Nieder S Petersen C Petersen HD Thames 2000 The challenge of p53 as prognostic and predictive factor in gliomas Cancer Treat Rev 26 1 67 73 1:CAS:528:DC%2BD3cXhvFeks78%3D 10.1053/ctrv.1999.0145 10660492
6. AP Kyritsis ML Bondy KR Hess JE Cunningham D Zhu CJ Amos WK Yung VA Levin JM Bruner 1995 Prognostic significance of p53 immunoreactivity in patients with glioma Clin Cancer Res 1 12 1617 1622 1:STN:280:DyaK1M%2FjsV2rsA%3D%3D 9815964
7. S al-Sarraj LR Bridges 1995 p53 immunoreactivity in astrocytomas and its relationship to survival Br J Neurosurg 9 2 143 149 1:STN:280: DyaK2MzlvVOruw%3D%3D 10.1080/02688699550041476 7632359
8. EC Burton KR Lamborn P Forsyth J Scott J O'Campo J Uyehara-Lock M Prados M Berger S Passe J Uhm BP O'Neill RB Jenkins KD Aldape 2002 Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors Clin Cancer Res 8 1 180 187 1:CAS:528:DC%2BD38XhsVKmu7w%3D 11801556
9. JM Cunningham DW Kimmel BW Scheithauer JR O'Fallon PJ Novotny RB Jenkins 1997 Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value J Neurosurg 86 1 121 130 1:STN:280:DyaK2s7ktFynsg%3D%3D 10.3171/jns.1997.86.1.0121 8988090
10. ML Grunnet A O'Neill M Gilbert R Hellman 2000 Correlation of tumor p53 and PCNA with response and survival of glioblastoma in patients treated with an ECOG protocol of pre-irradiation chemotherapy Clin Neuropathol 19 5 230 234 1:STN:280:DC%2BD3crgtFeitA%3D%3D 11048748
11. Perry A, Jenkins RB, O'Fallon JR, Schaefer PL, Kimmel DW, Mahoney MR, Scheithauer BW, Smith SM, Hill EM, Sebo TJ, Levitt R, Krook J, Tschetter LK, Morton RF, Buckner JC (1999) Clinicopathologic study of 85 similarly treated patients with anaplastic astrocytic tumors. An analysis of DNA content (ploidy), cellular proliferation, and p53 expression. Cancer 86(4):672-683
12. JF Reavey-Cantwell RI Haroun M Zahurak RE Clatterbuck RJ Parker R Mehta JP Fruehauf H Brem 2001 The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature J Neurooncol 55 3 195 204 1:STN:280:DC%2BD387isFGhsg%3D%3D 10.1023/A:1013845004294 11859975
13. P Iuzzolino C Ghimenton A Nicolato F Giorgiutti P Fina C Doglioni M Barbareschi 1994 p53 protein in low-grade astrocytomas: a study with long-term follow-up Br J Cancer 69 3 586 591 1:STN:280:DyaK2c7mvV2ksQ%3D%3D 8123492
14. C Sarkar AM Ralte MC Sharma VS Mehta 2002 Recurrent astrocytic tumors-a study of p53 immunoreactivity and malignant progression Br J Neurosurg 16 4 335 342 1:STN:280:DC%2BD38njtFGjuw%3D%3D 10.1080/02688697021000007588 12389885
15. A Tortosa N Viñolas S Villà E Verger JM Gil M Brell L Caral T Pujol JJ Acebes T Ribalta I Ferrer F Graus 2003 Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas Cancer 97 4 1063 1071 10.1002/cncr.11120 12569607
16. MKB Pakmar V Torri L Stewart 1998 Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints Stat Med 17 2815 2834 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID- SIM110>3.0.CO;2-8
17. LM Drach M Kammermeier U Neirich G Jacobi B Kornhuber R Lorenz W Schlote 1996 Accumulation of nuclear p53 protein and prognosis of astrocytomas in childhood and adolescence Clin Neuropathol 15 2 67 73 1:STN:280: DyaK283ntV2lsg%3D%3D 8925599
18. E Jaros RH Perry L Adam PJ Kelly PJ Crawford RM Kalbag AD Mendelow RP Sengupta AD Pearson 1992 Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumors Br J Cancer 66 2 373 385 1:STN:280:DyaK38zmvVyltA%3D%3D 1503912
19. BK Kleinschmidt-DeMasters L Meltesen L McGavran KO Lillehei 2006 Characterization of glioblastomas in young adults Brain Pathol 16 4 273 286 1:CAS:528:DC%2BD2sXkslKltw%3D%3D 10.1111/j.1750-3639.2006.00029.x 17107596
20. LJ Layfield C Willmore S Tripp C Jones RL Jensen 2006 Epidermal growth factor receptor gene amplification and protein expression in glioblastoma multiforme: prognostic significance and relationship to other prognostic factors Appl Immunohistochem Mol Morphol 14 1 91 96 1:CAS:528:DC%2BD28XivFCnsLw%3D 10.1097/01.pai.0000159772.73775.2e 16540738
21. AK Muhammad T Yoshimine M Maruno K Tokiyoshi O Takemoto H Ninomiya T Hayakawa 1997 Chromosome 17 allelic loss in astrocytic tumors and its clinico-pathologic implications Clin Neuropathol 16 4 220 226 1:STN:280:DyaK2svhtFWhtQ%3D%3D 9266149
22. A Vital H Loiseau G Kantor V Daucourt G Chene F Cohadon A Rougier J Rivel C Vital 1998 p53 protein expression in grade II astrocytomas: immunohistochemical study of 100 cases with long-term follow-up Pathol Res Pract 194 12 831 836 1:CAS:528:DyaK1MXitlGrtg%3D%3D 9894248
23. DC Martins SM Malheiros LH Santiago JN Stávale 2006 Gemistocytes in astrocytomas: are they a significant prognostic factor? J Neurooncol 80 1 49 55 1:CAS:528:DC%2BD28Xht12qtLvN 10.1007/s11060-006-9149-6 16645716
24. Saito T, Hama S, Kajiwara Y, Sugiyama K, Yamasaki F, Arifin MT, Arita K, Kurisu K (2006) Prognosis of cerebellar glioblastomas: correlation between prognosis and immunoreactivity for epidermal growth factor receptor compared with supratentorial glioblastomas. Anticancer Res 26(2B):1351-1357
25. Avninder S, Sharma MC, Deb P, Mehta VS, Karak AK, Mahapatra AK, Sarkar C (2006) Gemistocytic astrocytomas: histomorphology, proliferative potential and genetic alterations-a study of 32 cases. J Neurooncol 78(2):123-127. Epub 2006 Apr 14
26. Haapasalo JA, Nordfors KM, Hilvo M, Rantala IJ, Soini Y, Parkkila AK, Pastoreková S, Pastorek J, Parkkila SM, Haapasalo HK (2006) Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res 12(2):473-477
27. PM Ganigi V Santosh B Anandh BA Chandramouli VR Sastry Kolluri 2005 Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: a study of 54 patients Pediatr Neurosurg 41 6 292 299 1:STN:280:DC%2BD2MnhsFKhtA%3D%3D 10.1159/000088731 16293948
28. FS Pardo DW Hsu R Zeheb JT Efird PG Okunieff DM Malkin 2004 Mutant, wild type, or overall p53 expression: freedom from clinical progression in tumors of astrocytic lineage Br J Cancer 91 9 1678 1686 1:CAS:528:DC%2BD2cXptVOhurg%3D 15494720
29. Ribeiro Mde C, Coutinho LM, Hilbig A (2004) The role of apoptosis, cell proliferation index, bcl-2, and p53 in glioblastoma prognosis. Arq Neuropsiquiatr 62(2A):262-270. Epub 2004 Jun 23
30. RM Kirla HK Haapasalo H Kalimo EK Salminen 2003 Low expression of p27 indicates a poor prognosis in patients with high-grade astrocytomas Cancer 97 3 644 648 10.1002/cncr.11079 12548606
31. AM Stark HH Hugo P Witzel Z Mihajlovic HM Mehdorn 2003 Age-related expression of p53, Mdm2, EGFR and Msh2 in glioblastoma multiforme Zentralbl Neurochir 64 1 30 36 1:STN:280:DC%2BD3s%2Fnt1ersg%3D%3D 10.1055/s-2003-37149 12582944
32. A Korshunov A Golanov R Sycheva 2002 Immunohistochemical markers for prognosis of cerebral glioblastomas J Neurooncol 58 3 217 236 10.1023/A:1016218117251 12187957
33. A Korshunov A Golanov R Sycheva 2002 Immunohistochemical markers for prognosis of anaplastic astrocytomas J Neurooncol 58 3 203 215 10.1023/A:1016261900413 12187956
34. P Birner M Piribauer I Fischer B Gatterbauer C Marosi K Ungersböck K Rössler H Budka JA Hainfellner 2002 Prognostic relevance of p53 protein expression in glioblastoma Oncol Rep 9 4 703 707 1:CAS:528:DC%2BD38XltlGku7w%3D 12066196
35. A Peraud FW Kreth OD Wiestler P Kleihues HJ Reulen 2002 Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas Clin Cancer Res 8 5 1117 1124 1:CAS:528:DC%2BD38XksVSqu7g%3D 12006527
36. Hara A, Saegusa M, Mikami T, Okayasu I (2001) Loss of DCC expression in astrocytomas: relation to p53 abnormalities, cell kinetics, and survival. J Clin Pathol 54(11):860-865
37. Simmons ML, Lamborn KR, Takahashi M, Chen P, Israel MA, Berger MS, Godfrey T, Nigro J, Prados M, Chang S, Barker FG 2nd, Aldape K (2001) Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 61(3):1122-1128
38. H Haapasalo S Sallinen P Sallinen P Helén J Jää skeläinen TT Salmi A Paetau L Paljärvi T Visakorpi H Kalimo 1999 Clinicopathological correlation of cell proliferation, apoptosis and p53 in cerebellar pilocytic astrocytomas Neuropathol Appl Neurobiol 25 2 134 142 1:STN:280:DyaK1M3jsVaquw%3D%3D 10.1046/j.1365-2990.1999.00157.x 10216001
39. J Shinoda N Sakai K Nakatani T Funakoshi 1998 Prognostic factors in supratentorial WHO grade II astrocytoma in adults Br J Neurosurg 12 4 318 324 1:STN:280:DyaK1M7mvFGktA%3D%3D 10.1080/02688699844817 10070423
40. C Bouvier-Labit O Chinot C Ochi D Gambarelli H Dufour D Figarella-Branger 1998 Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas Neuropathol Appl Neurobiol 24 5 381 388 1:CAS:528:DyaK1cXnsFSgt74%3D 10.1046/j.1365-2990.1998.00137.x 9821169
41. SL Hwang YR Hong CY Chai HJ Lin SL Howng 1998 Prognostic evaluation in supratentorial astrocytic tumors using p53, epidermal growth factor receptor, c-erbB-2 immunostaining Kaohsiung J Med Sci 14 10 607 615 1:CAS:528: DyaK1cXnsFOjt74%3D 9819502
42. DA Hilton S Love R Barber D Ellison DR Sandeman 1998 Accumulation of p53 and Ki-67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy Neurosurgery 42 4 724 729 1:STN:280:DyaK1c3jtlyhsA%3D%3D 10.1097/00006123-199804000-00021 9574635
43. J Baxendine-Jones I Campbell D Ellison 1997 p53 status has no prognostic significance in glioblastomas treated with radiotherapy Clin Neuropathol 16 6 332 336 1:STN:280:DyaK1c%2FmsFegsQ%3D%3D 9401801
44. NG Rainov KU Dobberstein H Bahn HJ Holzhausen C Lautenschläger V Heidecke W Burkert 1997 Prognostic factors in malignant glioma: influence of the overexpression of oncogene and tumor-suppressor gene products on survival J Neurooncol 35 1 13 28 1:STN:280:DyaK2svhtFCmuw%3D%3D 10.1023/A:1005841520514 9266437
45. M Nakamura N Konishi S Tsunoda Y Hiasa T Tsuzuki T Inui T Sakaki 1997 Retinoblastoma protein expression and MIB-1 correlate with survival of patients with malignant astrocytoma Cancer 80 2 242 249 1:STN:280:DyaK2szmtVSjuw%3D%3D 10.1002/(SICI)1097-0142(19970715)80:2<242::AID-CNCR12>3.0.CO;2-U 9217037
46. P Korkolopoulou P Christodoulou K Kouzelis M Hadjiyannakis A Priftis G Stamoulis A Seretis E Thomas-Tsagli 1997 MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor Br J Cancer 75 9 1269 1278 1:STN:280:DyaK2s3pvFyqtA%3D%3D 9155045
47. DW Ellison PV Steart AC Bateman RM Pickering JD Palmer RO Weller 1995 Prognostic indicators in a range of astrocytic tumors: an immunohistochemical study with Ki-67 and p53 antibodies J Neurol Neurosurg Psychiatry 59 4 413 419 1:STN:280:DyaK28%2FivFCqug%3D%3D 10.1136/jnnp.59.4.413 7561922
48. RA Danks G Chopra MF Gonzales JM Orian AH Kaye 1995 Aberrant p53 expression does not correlate with the prognosis in anaplastic astrocytoma Neurosurgery 37 2 246 254 1:STN:280:DyaK28%2Fmsl2gsw%3D%3D 10.1227/00006123- 199508000-00009 7477776
49. TJ Montine JM Bruner JJ Vandersteenhoven RK Dodge PC Burger 1994 Prognostic significance of p53 immunoreactivity in adult patients with supratentorial fibrillary astrocytic neoplasms Diagn Mol Pathol 3 4 240 245 1:STN:280:DyaK2M7ntV2qsQ%3D%3D 10.1097/00019606-199412000-00005 7866633
50. Y Soini A Niemelä D Kamel R Herva R Bloigu P Pääkkö K Vähäkangas 1994 p53 immunohistochemical positivity as a prognostic marker in intracranial tumors Acta Pathol Microbiol Scand 102 10 786 792 1:STN:280:DyaK2M7islWqtA%3D%3D
51. P Hainaut M Hollstein 2000 p53 and human cancer: the first ten thousand mutations Adv Cancer Res 77 81 137 1:CAS:528:DC%2BD3cXltl2ktQ%3D%3D 10.1016/S0065-230X(08)60785-X 10549356
52. MS Greenblatt WP Bennett M Hollstein, et al. 1994 Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis Cancer Res 54 4855 4878 1:CAS:528:DyaK2cXlslKgsLw%3D 8069852
53. C Cordon-Cardo G Dalbagni GT Saez, et al. 1994 p53 mutations in human bladder cancer: genotypic versus phenotypic patterns Int J Cancer 56 347 353 1:STN:280:DyaK2c7kvVGgug%3D%3D 10.1002/ijc.2910560309 7906253
54. M Li CL Brooks N Kon W Gu 2004 A dynamic role of HAUSP in the p53-Mdm2 pathway Mol Cell 13 879 886 1:CAS:528:DC%2BD2cXjtFajsrc%3D 10.1016/S1097- 2765(04)00157-1 15053880
55. KT Kelsey T Hirao A Schned, et al. 2004 A population-based study of immunohistochemical detection of p53 alteration in bladder cancer Br J Cancer 90 1572 1576 1:CAS:528:DC%2BD2cXjtVWktbs%3D 10.1038/sj.bjc.6601748 15083187
56. D Wynford-Thomas 1992 Editorial: P53 in tumor pathology: can we trust immunohistochemistry? J Pathol 166 329 330 1:STN:280:DyaK38zovFSqtA%3D%3D 10.1002/path.1711660402 1517889
57. E Steels M Paesmans T Berghmans F Branle F Lemaitre C Mascaux AP Meert F Vallot JJ Lafitte JP Sculier 2001 Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis Eur Respir J 18 4 705 719 1:CAS:528:DC%2BD3MXpt1Kisrw%3D 10.1183/09031936.01.00062201 11716177
58. RC Bast Jr P Ravdin DF Hayes, et al. 2001 American Society of Clinical Oncology Tumor Markers Expert Panel. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology J Clin Oncol 19 1865 1878 11251019
59. DG Altman B Lausen W Sauerbrei, et al. 1994 Dangers of using "optimal" cutpoints in the evaluation of prognostic factors J Natl Cancer Inst 86 829 835 1:STN:280:DyaK2c3jvVOjtQ%3D%3D 10.1093/jnci/86.11.829 8182763
60. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol 2(8):416-422
61. L Stewart MKB Parmar 1993 Meta-analysis of the literature or individual patient data; is there a difference? Lancet 341 418 422 1:STN:280: DyaK3s7ls1GitA%3D%3D 10.1016/0140-6736(93)93004-K 8094183
62. RD Riley SA Burchill KR Abrams, et al. 2003 A systematic review and evaluation of the use of tumor markers in paediatric oncology: Ewing's sarcoma and neuroblastoma Health Technol Assess 7 1 162 1:STN:280:DC%2BD3s7itVaqtg%3D%3D 12633526
63. N Malats A Bustos CM Nascimento F Fernandez M Rivas D Puente M Kogevinas FX Real 2005 P53 as a prognostic marker for bladder cancer: a meta-analysis and review Lancet Oncol 6 9 678 686 1:CAS:528:DC%2BD2MXpslynsro%3D 10.1016/S1470-2045(05)70315-6 16129368
64. C Cordon-Cardo 2004 p53 and Rb: simple interesting correlates or tumor markers of clinical predictive nature? J Clin Oncol 22 1 3 10.1200/JCO.2004.12. 994
65. A Laupacis G Wells WS Richardson for the Evidence-Based Medicine Working Group, et al. 1994 Users' guides to the medical literature V: how to use an article about prognosis J Am Med Assoc 272 234 237 1:STN:280: DyaK2c3ptlCnsA%3D%3D 10.1001/jama.272.3.234